Amarin Corporation plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Aaron D. Berg
- Full Time Employees
- 80
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Central Plaza Dublin DU Ireland 2
- IPO Date
- Apr 1, 1993
- CIK
- 0000897448
- Website
- amarincorp.com
- Similar Companies
- Business
- Amarin Corporation plc is a biopharmaceutical company focused on the development, commercialization, and advancement of therapeutics to improve cardiovascular health and reduce cardiovascular risk. The company primarily markets its lead product, Vascepa (icosapent ethyl) in the United States and Vazkepa in Europe, prescription-grade omega-3 fatty acid capsules used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia and to lower the risk of cardiovascular events. Amarin's broad product offerings center on cardiovascular disease treatments, specifically addressing lipid disorders through their omega-3 therapies. The company operates globally with commercial activities spanning the United States, Europe, and other international markets through partnerships and licensing arrangements. Founded in 1989 and headquartered in Dublin, Ireland, with operational facilities in the United States, Amarin has recently undergone major strategic changes focused on expanding its global presence and increasing operational efficiency. In 2025, Amarin completed a transition to a fully partnered commercialization model outside the United States, partnering with seven collaborators across nearly 100 countries to leverage established commercial infrastructure and drive broader access to its therapies. The company implemented a global corporate restructuring in 2025 designed to reduce operating expenses by an estimated $70 million over 12 months, including a significant workforce reduction in Europe to align with the new partnership model. Additionally, Amarin is focused on accelerating in-market demand in Europe through a partnership with Recordati to commercialize Vazkepa. These strategic initiatives reflect Amarin's efforts to adapt to market challenges, including competition from generic alternatives and a shifting operational footprint, while positioning for sustainable growth and improved cash flow. The company continues to invest in research and development to pursue additional cardiovascular therapeutics and enhance its portfolio. Amarin retains significant financial assets including nearly $300 million in cash and operates with no debt, supporting its ongoing strategic objectives and shareholder value creation efforts. The company sells products through wholesalers, regional distributors, and specialty pharmacy providers, serving diverse healthcare markets primarily focused on cardiovascular disease risk reduction. Amarin's corporate strategy emphasizes innovation, global market expansion through partnerships, and operational discipline to drive future growth.
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
Amarin Q2 Earnings Call Highlights
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Amarin Reports 2026 First Quarter Financial Results
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin Q4 Earnings Call Highlights